30 related articles for article (PubMed ID: 9925736)
1. Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure.
Arendse LB; Danser AHJ; Poglitsch M; Touyz RM; Burnett JC; Llorens-Cortes C; Ehlers MR; Sturrock ED
Pharmacol Rev; 2019 Oct; 71(4):539-570. PubMed ID: 31537750
[TBL] [Abstract][Full Text] [Related]
2. Targeting Metalloenzymes for Therapeutic Intervention.
Chen AY; Adamek RN; Dick BL; Credille CV; Morrison CN; Cohen SM
Chem Rev; 2019 Jan; 119(2):1323-1455. PubMed ID: 30192523
[TBL] [Abstract][Full Text] [Related]
3. Continuous flow photolysis of aryl azides: Preparation of 3H-azepinones.
Bou-Hamdan FR; Lévesque F; O'Brien AG; Seeberger PH
Beilstein J Org Chem; 2011; 7():1124-1129. PubMed ID: 21915216
[TBL] [Abstract][Full Text] [Related]
4. Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors.
Robl JA; Cimarusti MP; Simpkins LM; Brown B; Ryono DE; Bird JE; Asaad MM; Schaeffer TR; Trippodo NC
J Med Chem; 1996 Jan; 39(2):494-502. PubMed ID: 8558518
[TBL] [Abstract][Full Text] [Related]
5. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
Fink CA; Carlson JE; McTaggart PA; Qiao Y; Webb R; Chatelain R; Jeng AY; Trapani AJ
J Med Chem; 1996 Aug; 39(16):3158-68. PubMed ID: 8759637
[TBL] [Abstract][Full Text] [Related]
6. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.
Fournie-Zaluski MC; Coric P; Thery V; Gonzalez W; Meudal H; Turcaud S; Michel JB; Roques BP
J Med Chem; 1996 Jun; 39(13):2594-608. PubMed ID: 8691458
[TBL] [Abstract][Full Text] [Related]
7. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
Robl JA; Sun CQ; Stevenson J; Ryono DE; Simpkins LM; Cimarusti MP; Dejneka T; Slusarchyk WA; Chao S; Stratton L; Misra RN; Bednarz MS; Asaad MM; Cheung HS; Abboa-Offei BE; Smith PL; Mathers PD; Fox M; Schaeffer TR; Seymour AA; Trippodo NC
J Med Chem; 1997 May; 40(11):1570-7. PubMed ID: 9171867
[TBL] [Abstract][Full Text] [Related]
8. Vasopeptidase inhibitors: incorporation of geminal and spirocyclic substituted azepinones in mercaptoacyl dipeptides.
Robl JA; Sulsky R; Sieber-McMaster E; Ryono DE; Cimarusti MP; Simpkins LM; Karanewsky DS; Chao S; Asaad MM; Seymour AA; Fox M; Smith PL; Trippodo NC
J Med Chem; 1999 Jan; 42(2):305-11. PubMed ID: 9925736
[TBL] [Abstract][Full Text] [Related]
9. Vasopeptidase inhibition: a new concept in blood pressure management.
Burnett JC
J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
[TBL] [Abstract][Full Text] [Related]
10. Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
Nawarskas J; Rajan V; Frishman WH
Heart Dis; 2001; 3(6):378-85. PubMed ID: 11975822
[TBL] [Abstract][Full Text] [Related]
11. Vasopeptidase inhibition: a double-edged sword?
Campbell DJ
Hypertension; 2003 Mar; 41(3):383-9. PubMed ID: 12623931
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
